JP2024547218A5 - - Google Patents

Info

Publication number
JP2024547218A5
JP2024547218A5 JP2024556825A JP2024556825A JP2024547218A5 JP 2024547218 A5 JP2024547218 A5 JP 2024547218A5 JP 2024556825 A JP2024556825 A JP 2024556825A JP 2024556825 A JP2024556825 A JP 2024556825A JP 2024547218 A5 JP2024547218 A5 JP 2024547218A5
Authority
JP
Japan
Application number
JP2024556825A
Other languages
Japanese (ja)
Other versions
JP2024547218A (ja
JPWO2023112028A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2022/051321 external-priority patent/WO2023112028A1/en
Publication of JP2024547218A publication Critical patent/JP2024547218A/ja
Publication of JP2024547218A5 publication Critical patent/JP2024547218A5/ja
Publication of JPWO2023112028A5 publication Critical patent/JPWO2023112028A5/ja
Pending legal-status Critical Current

Links

JP2024556825A 2021-12-13 2022-12-13 Ig様融合タンパク質およびその使用 Pending JP2024547218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288782P 2021-12-13 2021-12-13
US63/288,782 2021-12-13
PCT/IL2022/051321 WO2023112028A1 (en) 2021-12-13 2022-12-13 Ig-like fusion proteins and use thereof

Publications (3)

Publication Number Publication Date
JP2024547218A JP2024547218A (ja) 2024-12-26
JP2024547218A5 true JP2024547218A5 (https=) 2025-12-23
JPWO2023112028A5 JPWO2023112028A5 (https=) 2025-12-23

Family

ID=86774007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556825A Pending JP2024547218A (ja) 2021-12-13 2022-12-13 Ig様融合タンパク質およびその使用

Country Status (6)

Country Link
US (1) US20250059255A1 (https=)
EP (1) EP4447993A4 (https=)
JP (1) JP2024547218A (https=)
CN (1) CN118678964A (https=)
CA (1) CA3240617A1 (https=)
WO (1) WO2023112028A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120500348A (zh) * 2022-12-13 2025-08-15 卡努佩免疫治疗公司 用于治疗重症肌无力的Ig样融合蛋白
WO2025030000A1 (en) * 2023-08-01 2025-02-06 Merida Biosciences, Inc. Molecules for controlling autoimmune response
AU2024318666A1 (en) * 2023-08-01 2026-01-22 Merida Biosciences, Inc. Molecules for controlling autoimmune response
WO2025126210A1 (en) * 2023-12-13 2025-06-19 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating musk myasthenia gravis
WO2025126216A1 (en) * 2023-12-13 2025-06-19 Canopy Immuno-Therapeutics Ltd. Improved acetylcholine receptor molecules and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100719020B1 (ko) * 2005-09-28 2007-05-17 광주과학기술원 재조합 아세틸콜린 수용체 폴리펩티드, 폴리펩티드 유도체및 이를 유효성분으로 포함하는 중증근무력증 치료제
JP4857396B1 (ja) * 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
WO2016044137A2 (en) * 2014-09-15 2016-03-24 The Trustees Of The University Of Pennsylvania Acetylcholine receptor-specific immunosuppressive compositions and methods of treatment of myasthenia gravis

Similar Documents

Publication Publication Date Title
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
CN307047033S (https=)
BY13135U (https=)
BY13137U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13145U (https=)
CN307046319S (https=)